Prof. Fulvio ERBA
Biografia
2014:Modulo Biochimica, corso di laurea in Infermieristica Pediatrica, Ospedale Bambino Gesù, Roma.
2014:Modulo Biochimica, CdL Odontoiatria, Università Signora del Buon Consiglio, Tirana, Albania.
2011:Modulo Biochimica, corso di laurea di afferenti terzo Tronco Comune, Università degli Studi di Roma Tor Vergata.
2010:Modulo Biochimica, corso di laurea in Fisioterapia e in Logopedia, Università degli Studi di Roma Tor Vergata, presso Fondazione Santa Lucia IRCCS, Roma.
2004 – 2010:Membro del Collegio di Dottorato di Ricerca in Microbiologia Medica e Immunologia, Università degli Studi di Roma Tor Vergata.
2001:Modulo Biochimica, corso di laurea in Igiene Dentale.
Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi, Giuliano M, Galluzzo CM, Mancinelli S, Andreotti M, Jere H, Sagno JB, Maulidi M, Erba F, Amici R, Buonomo E, Scarcella P, Marazzi MC, Vella S, Palombi L, J Trop Pediatr, 2015.
HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique, Borgiani P, Di Fusco D, Erba F, Marazzi MC, Mancinelli S, Novelli G, Palombi L, Ciccacci C, Eur J Clin Pharmacol, 2014 Mar, 70(3):275-8.
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study, Ciccacci C, Di Fusco D, Marazzi MC, Zimba I, Erba F, Novelli G, Palombi L, Borgiani P, Liotta G, Eur J Clin Pharmacol, 2013 Nov, 69(11):1909-16.
Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi, Galluzzo C, Liotta G, Andreotti M, Luhanga R, Jere H, Mancinelli S, Maulidi M, Sagno JB, Pirillo M, Erba F, Amici R, Ceffa S, Marazzi MC, Vella S, Palombi L, Giuliano M, Med Virol, 2012 Oct, 84(10):1553-7.
Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety, Palombi L, Pirillo MF, Andreotti M, Liotta G, Erba F, Sagno JB, Maulidi M, Ceffa S, Jere H, Marchei E, Pichini S, Galluzzo CM, Marazzi MC, Vella S, Giuliano M, Antivir Ther, 2012, 17(8):1511-9.
Nutritional rehabilitation of HIV-exposed infants in Malawi: results from the drug resources enhancement against AIDS and malnutrition program, Buonomo E, de Luca S, Tembo D, Scarcella P, Germano P, Doro Altan AM, Palombi L, Liotta G, Nielsen-Saines K, Erba F, Marazzi MC, Int J Environ Res Public Health , 2012 Feb , 9(2):421-3.
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme, Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, Svicher V, D'Arrigo R, Emberti-Gialloreti L, Ceffa S, Erba F, Marazzi MC, Silberstein FC, Perno CF, J Med Virol, 2005 Aug, 76(4):452-8.
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure, Ceccherini-Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF, AIDS, 2004 Aug, 20;18(12).
Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug, Erba F, Fiorucci L, Pascarella S, Menegatti E, Ascenzi P, Ascoli F, Biochem Pharmacol, 2001 Feb, 1;61(3):271-6.
Kinetic and thermodynamic analysis of leech-derived tryptase inhibitor interaction with bovine tryptase and bovine trypsin, Biol Chem., Erba F, Fiorucci L, Sommerhoff CP, Coletta M, Ascoli F, 2000 Nov, 381(11):1117-22.
